α-骨化醇(BONE-ONE)治疗Ⅱ型糖尿病合并骨质疏松症的临床观察  

CLINICAL EFFECT OF BONE-ONE ON OSTEOPOROSIS IN DIABETIC PATIENTS

作　　者：黄丹珊[1] 粱斌 高妍[1] 陈澜[1] 王淑凤 

机构地区：[1]北京医科大学第一医院内分泌科

出　　处：《中国临床药理学杂志》1998年第1期1-6,共6页The Chinese Journal of Clinical Pharmacology

摘　　要：本研究目的在于观察α－骨化醇（ＢＯＮＥ－ＯＮＥ）对糖尿病合并骨质疏松长期治疗的安全性和有效性。绝经后女性Ⅱ型糖尿病合并骨质疏松２９例，随机选择其中２０例为糖尿病治疗组，９例为糖尿病对照组，年龄等相匹配老年女性骨质疏松１０例（老年治疗组）共三组病人进行６个月药物治疗，糖尿病治疗组及老年治疗组服用α－骨化醇剂量为０．５μｇ·ｄ－１。研究结果：糖尿病与老年治疗组在治疗３个月、６个月后骨密度增高、骨形成指标增加（ＢＰＧ）、骨吸收指标减少（Ｃｒｏｓｓｌａｐ／Ｃｒ）和骨痛缓解率明显增加，分别是：骨密度由０．３２３±０．０１，０．２９７±０．０３（ｇ／ｃｍ２）升至０．４１５±０．０６，０．３７８±０．０３（ｇ／ｃｍ２）；ＢＧＰ由１０．１９±０．７９，９．２４±１．２６（ｍｇ·Ｌ－１）升至１５．８９±０．１２，１４．５５±１．１２（ｍｇ·Ｌ－１）；骨吸收指标Ｃｒｏｓｌａｐ／Ｃｒ由３６３．７±９１．３，４２０．２±１０７．９（μｇ·ｍｍｏｌ－１）减至２２６．９±５３．７，１６２．１４±５３．７（μｇ·ｍｍｏｌ－１）但两组间无显著差异，糖尿病对照组无变化。研究结果表明：糖尿病合并骨质疏松病人在良好控制血糖基础上服用α－骨化醇?In order to assess the effect of Bone-One (alfacalcidol) on diabetic patients with osteoporosis in long term therapy. 29 diabetic patients with osteoporosis were studied.They were separated into two groups randomly: 20 diabetic patients with osteoporosis as diabetic treated group, 9 diabetic patients with osteoporosis as control group as well as another 10 matched patients having senile osteoporosis as senile treated group. Two treated groups took Bone-One 0.5 μg·d-1 for 6 months. The results were as follows: In groups of senile treated group and diabetic treated group, the bone mineral density (BMD) were higher than before and serum osteocalcin (BGP) which stands for bone turn over had a great increase, Crosslaps/Cr which stands for bone resorption capability had a great decrease. The observed parameters were greatly improved , the relief rate of bone pain were markedly increased in 3-months, 6-months treatment. In diabetic treated group and senile treated group BMD from 0.323±0.01, 0.297±0.03(g/cm2) to 0.415±0.06, 0.378±0.03(g/cm2); BGP from 10.19±0.79,9.24±1.26(mg·L-1) to 15.89±0.12,14.55±1.12(mg·L-1); Crosslap/Cr from 363.7±91.3, 420.2±107.9 (μg·mmol-1) to 226.9±53.7, 162.14±53.7 (μg·mmol-1) respectively, but there was no statistically significant deference between these two groups. There were no effects in control group. The study had shown that based on a good control of blood glucose, Bone-One was remarkable effective on the treatment diabetic patients with osteoporosis as well as patients having senile osteoporosis. No adverse drug reactions were observed in two treated groups.

关 键 词：α骨化醇 糖尿病 骨质疏松 并发症 药物疗法 

分 类 号：R587.205[医药卫生—内分泌] R681.05[医药卫生—内科学]